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RESEARCH ARTICLE
The effectiveness of treatment with enoxaparin in lichen planus
Liken planusda enoxaparin tedavisinin etkinliği
Derya Uçmak, Gökçen Balcı, Mehmet Harman
Department of Dermatology, Dicle University Faculty of Medicine, Diyarbakır, Turkey
ÖZET
Amaç: Heparin analoglarının düşük dozlarının antiproli-
feratif ve immünmodülatör etkilerinin olduğu bilinmektedir. 
Bu çalışmanın amacı; liken planusta düşük doz enoxapa-
rinin etkinliğini değerlendirmektir.
Gereç ve yöntem: Liken planus tanısı alan 21 hasta 12 
hafta  boyunca  tedavi  edildi.  Hastalara  her  hafta  3  mg 
enoxaparin subkutan enjeksiyonla yapıldı. Etki ve güven-
lik verileri kaydedildi.
Bulgular: Tam iyileşme hastaların 15’ inde (%71), belirgin 
düzelme 4’ ünde (%19) tespit edildi. Hastaların 2’sinde 
(%9) tedaviye yanıt alınmadı. Tedavi sonucunda en iyi ya-
nıt, liken planusun akut generalize tipinde görüldü.
Sonuç: Sonuç olarak enoxaparin tedavisinin liken planus-
ta etkili bir tedavi seçeneği olabileceği kanaatine varıldı.
Anahtar kelimeler: Liken planus, enoxaparin, tedavi
ABSTRACT
Objectives: As it is known, the low doses of Heparin’s 
analogues have the antiproliferative and immunomodula-
tor activities. This research aims to evaluate the activity of 
enoxaparin by using the low doses.
Materials and methods: 21 patients with lichen planus 
diagnosis  have  been  cured  within  12  weeks.  3  mg  of 
enoxaparin has been used for subcutaneus injection to 
all of patients weekly. The efficient and reliable data has 
been saved.
Results:  The  perfect  recovery  has  been  observed  15 
(71%) of 21 patients, the distinct recovery has been ob-
served  4  (19%)  of  21  patients. The  treatment  has  not 
given response on 2 (9%) of 21 patients. The best score 
has been received on acute generalized type of Lichen 
Planus.
Conclusions: As  the  result;  it  has  been  reported  that 
enoxaparin treatment can be an effective choice in Lichen 
Planus medication. J Clin Exp Invest 2011; 3(2): 172-173
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INTRODUCTION
Lichen Planus is a common, chronic and inflamma-
tory mucocutaneous disease which affects 0,9-1,2 
% of the general population.1 The mucosal accumu-
lations frequently occur and it can rarely cause to 
nail dystrophy or cicatricial alopecia. There are vari-
ous clinical types of Lichen Planus and the course 
of disease is unpredictable.2 The Lichen Planus is 
characterized by the interface dermatitis which is 
occurred intensely infiltration of lymphocytes along 
dermal-epidermal junction and vacuolar degenera-
tion and destruction of keratinocytes on stratum ba-
sale.1
Apoptosis of T-lymphocytes and keratinocytes 
which are contained in dermal infiltrate cause the 
destruction of epidermis. The clinical and histologi-
cal indicators are similar as chronic graft-versus host 
reaction.3 Lichen Planus may consist the response 
of antigenic impluse in epidermis as the delayed-
type hypersensitivity (DTH) reactions.1,4
Except  the  anti-coagulan  activity  of  very  low 
doses of heparin; it is point out that it inhibits type-
IV reaction in T-lymphocytes sourced otoimmun dis-
eases and on the allografted mouses.2 Also sulphat-
ed glycosaminoglycan heparin has anti-proliferative 
effects via activity interaction with keratinocyte gen-
erated, heparin-binding autocrine growth factors.1
Enoxaparin  is  low-molecular-weight  heparin. 
The dominances of enoxaparin are longer half-life, 
easier to dose and more reliable than heparin. On 
the outside of anti-coagulant activity of enoxaparin, 
various  researches  are  shown  that  it  is  effective 
on lichen planus and allergic contact dermatitis in 
vivo.3,5 In this research; 21 lichen planus patients is 
cured with enoxaparine and clinical responses are 
analysed.D. Uçmak et al. Enoxaparin treatment in lichen planus 173
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MATERIALS AND METHODS
The research is experienced in 22 patients (15 fe-
male and 7 male) who are between 17-60 years 
old. Lichen Planus is histologically verified on all of 
them. The duration of this disease has been taken 
for 2 months to 3 years. The history of taking medi-
cine causing the similar lesion as lichen planus was 
not noticed on any patient.
Their systemic or local treatment was stopped 
at least 8 weeks before this research started. Enoxa-
parin was injected subcutaneously at a concentra-
tion of 3mg per week. The patients have been eval-
uated every week and each time they were quested 
about the itchiness and its degree, the effectiveness 
was divided into the stages by clinical evaluation. 
Haemogram, blood biochemical constituents, coag-
ulation factors were evaluated once a week before 
and also during treatment. The patients who took 
the 12 weeks medication and had been checked up 
during 6 months after treatment were analyzed.
RESULTS
The research was completed on 21 of 22 patients 
successfully.  However,  The  perfect  recovery  was 
observed 15 (71%) of 21 patients,the distinct recov-
ery was observed 4 (19%) of 21 patients. The treat-
ment did not responsed on 2 (9%) of 21 patients. 
Also the patients did not react on any side effect. Six 
months after the treatment; recurrence is noticed on 
two patients. The best reponse was received on the 
acute generalized type lichen planus lesions. After 
the 2nd -3rd injection, pruritus was reduced and the 
5th -6th one, it was receded completely.
DISCUSSION
The  active  T-lymphocytes  secrete  enzyme  hepa-
ranase to pass vascular barriers, to penetrate extra-
cellular matrix and to accumulate in target tissue.1,3 
The chemical properties of heparin is similar like 
heparan sulphate which is a component of dermal-
extracelluler-matrix.heparan  sulphate  may  cause 
competitive inhibition by occupying the part of sub-
tance that enzyme heparanase conjugates.1,2,6
In  the  present  study  we  investigated  the  ef-
fects in vitro and in vivo of the heparanase inhibi-
tor,  heparin,  on  the  expression  of  T  lymphocyte 
heparanase and on the ability of T lymphocytes to 
mediate a delayed-type hypersensitivity (DTH) re-
action.6 The low-molecular-weight heparin reduces 
translocation of tumor necrosis factor alfa (TNF-a), 
interleukin (IL)-8, IL-6, IL-1B and nuclear factor (NF) 
kappa B (kB) which are caused by lipopolysaccha-
rides distinctly.7 Enoxaparin is low-molecular-weight 
heparin.  Epidemically  it  is  used  at  treatment  of 
thromboembolic diseases as similar like other low-
molecular-weight  heparin;  it  has  the  better  phar-
maco-dynamic  parametres  (properties)  and  more 
reliable than heparin. They effect by inhibiting factor 
Xa.8 The researches about enoxaparin on Lichen 
Planus  provide  the  different  results.  Ferahbas  et 
al. treated 10 patients and enoxaparin was injected 
SC for 5mg/week. They observed that enoxaparin is 
non-effective except reducing pruritus.2 At the other 
hand, studies have shown that on the treatment of 
lichen  planus  patients,  enoxaparin  treatment  is  a 
basic and effective method.1,3,9 Yaşar et al. reported 
two patient with palmoplantar lichen planus, which 
were successfully treated by subcutaneous enoxa-
parin without any subsequent adverse effects.10
The self-limited course of lichen planus prob-
ably may be difficult to evaluate the efficiency of 
treatment. In case, spontaneous resolution is gen-
erally slow.3 The quick recovery and continuous re-
mission advocate that enoxaparin might be useful 
for cutaneous lichen planus. As the result, this re-
search advocates other researches remarking that 
the  treatment  of  enoxaparin  is  an  effective  treat-
ment choice for lichen planus.
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